{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T06:06:17Z","timestamp":1759385177178,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Jiangsu Innovation Support Programme for Soft Science Research","award":["BR2023018-5"],"award-info":[{"award-number":["BR2023018-5"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s11096-024-01706-0","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T21:22:41Z","timestamp":1710278561000},"page":"694-703","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Availability, price, and affordability of anti-hepatitis B virus drugs: a cross-sectional study in China"],"prefix":"10.1007","volume":"46","author":[{"given":"Yue","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengdie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5948-4762","authenticated-orcid":false,"given":"Tao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"1706_CR1","unstructured":"World Health Organization. Health topics, Hepatitia. 2023. https:\/\/www.who.int\/zh\/health-topics\/hepatitis#tab=tab_1,2023. Accessed 1 Jun 2023."},{"issue":"10003","key":"1706_CR2","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546\u201355.","journal-title":"Lancet"},{"issue":"17","key":"1706_CR3","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jama.2018.3795","volume":"319","author":"LSY Tang","year":"2018","unstructured":"Tang LSY, Covert E, Wilson E, et al. Chronic hepatitis B infection: a review. JAMA. 2018;319(17):1802\u201313.","journal-title":"JAMA"},{"issue":"4","key":"1706_CR4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","volume":"45","author":"JF Perz","year":"2006","unstructured":"Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529\u201338.","journal-title":"J Hepatol"},{"issue":"29","key":"1706_CR5","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1200\/JCO.22.01051","volume":"40","author":"LR Roberts","year":"2022","unstructured":"Roberts LR. Untreated chronic hepatitis B is associated with a higher risk of extrahepatic malignancies. J Clin Oncol. 2022;40(29):3357\u201360.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1706_CR6","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/14787210.2023.2225771","volume":"21","author":"C Forbes","year":"2023","unstructured":"Forbes C, Lavoie L, Satram S, et al. Global importance of new treatment strategies to efforts to control hepatitis B virus. Expert Rev Anti Infect Ther. 2023;21(8):847\u201362. https:\/\/doi.org\/10.1080\/14787210.2023.2225771.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1706_CR7","unstructured":"National Health Commission of the People's Republic of China. 2021 China Health Care Statistics Yearbook. 2022. http:\/\/www.nhc.gov.cn\/mohwsbwstjxxzx\/tjtjnj\/202305\/304a301bfdb444afbf94b1a6c7f83bca.shtml. Accessed 1 Jun 2023."},{"issue":"8","key":"1706_CR8","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.cgh.2023.04.015","volume":"21","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Wong G, Anstee QM, et al. The global burden of liver disease. Clin Gastroenterol Hepatol. 2023;21(8):1978\u201391.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"05","key":"1706_CR9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.19914\/j.cjvi.2019.05.027","volume":"25","author":"YM Wan","year":"2019","unstructured":"Wan YM, Wang FZ, Zhang GM, et al. Risk of hepatitis B infection and burden of disease in adults. China Vaccine Immunity. 2019;25(05):611\u20136. https:\/\/doi.org\/10.19914\/j.cjvi.2019.05.027.","journal-title":"China Vaccine Immunity"},{"issue":"05","key":"1706_CR10","doi-asserted-by":"publisher","first-page":"464","DOI":"10.16250\/j.32.1374.2023068","volume":"35","author":"LX Yao","year":"2023","unstructured":"Yao LX, Lin S, Huang JF, et al. Analysis and prediction of the burden of disease of viral hepatitis B-related diseases in China from 1990 to 2030. Chin J Schistosomiasis Control. 2023;35(05):464\u201375+496. https:\/\/doi.org\/10.16250\/j.32.1374.2023068.","journal-title":"Chin J Schistosomiasis Control"},{"issue":"3","key":"1706_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/jvh.12482","volume":"23","author":"S Zhang","year":"2016","unstructured":"Zhang S, Ma Q, Liang S, et al. Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China. J Viral Hepatitis. 2016;23(3):202\u201310.","journal-title":"J Viral Hepatitis"},{"issue":"2","key":"1706_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s12072-015-9661-x","volume":"10","author":"N Yang","year":"2016","unstructured":"Yang N, Bertoletti A. Advances in therapeutics for chronic hepatitis B. Hepatol Int. 2016;10(2):277\u201385.","journal-title":"Hepatol Int"},{"issue":"6","key":"1706_CR13","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1007\/s11096-015-0193-1","volume":"37","author":"JH Kim","year":"2015","unstructured":"Kim JH, Jung SW, Byun SS, et al. Efficacy and safety of tenofovir in nucleos(t)ide-na\u00efve patients with genotype C chronic hepatitis B in real-life practice. Int J Clin Pharm. 2015;37(6):1228\u201334. https:\/\/doi.org\/10.1007\/s11096-015-0193-1.","journal-title":"Int J Clin Pharm"},{"issue":"33","key":"1706_CR14","first-page":"17","volume":"13","author":"Q Lu","year":"2020","unstructured":"Lu Q. Analysis of the use of nucleoside (acid) analogues anti-hepatitis B virus drugs in the Third Hospital Affiliated to Nantong University from 2017\u20132019. J Clin Ration Drug Use. 2020;13(33):17\u201320+24.","journal-title":"J Clin Ration Drug Use"},{"issue":"9","key":"1706_CR15","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/hiv.13280","volume":"23","author":"D Rupasinghe","year":"2022","unstructured":"Rupasinghe D, Choi JY, Kumarasamy N, et al. Viral hepatitis and the cascade of care among people living with HIV in the Asia-Pacific. HIV Med. 2022;23(9):959\u201368. https:\/\/doi.org\/10.1111\/hiv.13280.","journal-title":"HIV Med"},{"issue":"5","key":"1706_CR16","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/infdis\/jiab562","volume":"226","author":"AJ Stockdale","year":"2022","unstructured":"Stockdale AJ, Meiring JE, Shawa IT, et al. Hepatitis B vaccination impact and the unmet need for antiviral treatment in Blantyre, Malawi. J Infect Dis. 2022;226(5):871\u201380. https:\/\/doi.org\/10.1093\/infdis\/jiab562.","journal-title":"J Infect Dis"},{"issue":"5","key":"1706_CR17","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/tmi.13559","volume":"26","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Xu X, Fang W, et al. Availability, cost and affordability of selected antibiotics and antiviral medicines against infectious diseases from 2013 to 2019 in Nanjing, China. Trop Med Int Health. 2021;26(5):518\u201329.","journal-title":"Trop Med Int Health"},{"issue":"5","key":"1706_CR18","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1007\/s11096-019-00889-1","volume":"41","author":"MH Duong","year":"2019","unstructured":"Duong MH, Moles RJ, Chaar B, et al. Stakeholder perspectives on the challenges surrounding management and supply of essential medicines. Int J Clin Pharm. 2019;41(5):1210\u20139. https:\/\/doi.org\/10.1007\/s11096-019-00889-1.","journal-title":"Int J Clin Pharm"},{"issue":"17","key":"1706_CR19","first-page":"9","volume":"32","author":"XY Qi","year":"2023","unstructured":"Qi XY, Li ZR, Hao ZY. Analysis of the impact of the centralised procurement policy of state-organised drugs on the clinical application of selected ganciclovir and entecavir based on the interrupted time series method. China Pharm Ind. 2023;32(17):9\u201312.","journal-title":"China Pharm Ind"},{"key":"1706_CR20","doi-asserted-by":"publisher","first-page":"842944","DOI":"10.3389\/fphar.2022.842944","volume":"13","author":"J Yuan","year":"2022","unstructured":"Yuan J, Lu ZK, Xiong X, et al. Impact of national volume-based procurement on the procurement volumes and spending for antiviral medications of hepatitis B virus. Front Pharmacol. 2022;13:842944. https:\/\/doi.org\/10.3389\/fphar.2022.842944.","journal-title":"Front Pharmacol"},{"key":"1706_CR21","unstructured":"World Health Organization. WHO model lists of essential medicines. 2023. http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/. Accessed 22 Aug 2023."},{"key":"1706_CR22","unstructured":"Central Government of the People\u2019s Republic of China, Departmental documents of the State Council. National Health Insurance Bureau Ministry of Human Resources and Social Security on the Issuance of the National Catalogue of Medicines for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (2022). https:\/\/www.gov.cn\/zhengce\/zhengceku\/2023-01\/18\/content_5737840.htm. Accessed 22 Aug 2023."},{"issue":"1","key":"1706_CR23","first-page":"3","volume":"41","author":"Chinese Medical Association Hepatology Branch, Chinese Medical Association Infectious Diseases Branch","year":"2023","unstructured":"Chinese Medical Association Hepatology Branch, Chinese Medical Association Infectious Diseases Branch. Guidelines for the prevention and treatment of chronic hepatitis B. Chin J Infect Dis. 2023;41(1):3\u201328.","journal-title":"Chin J Infect Dis"},{"issue":"10","key":"1706_CR24","doi-asserted-by":"publisher","first-page":"e023646","DOI":"10.1136\/bmjopen-2018-023646","volume":"8","author":"X Sun","year":"2018","unstructured":"Sun X, Wei J, Yao Y, et al. Availability, prices and affordability of essential medicines for children: a cross-sectional survey in Jiangsu Province, China. BMJ Open. 2018;8(10):e023646.","journal-title":"BMJ Open"},{"issue":"8","key":"1706_CR25","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1093\/heapol\/czy076","volume":"33","author":"S Gong","year":"2018","unstructured":"Gong S, Cai H, Ding Y, et al. The availability, price and affordability of antidiabetic drugs in Hubei province, China. Health Policy Plan. 2018;33(8):937\u201347.","journal-title":"Health Policy Plan"},{"issue":"suppl_1","key":"1706_CR26","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","volume":"42","author":"S Leucht","year":"2016","unstructured":"Leucht S, Samara M, Heres S, et al. Dose equivalents for antipsychotic drugs: the DDD method. Schizophrenia Bull. 2016;42(suppl_1):S90\u20134.","journal-title":"Schizophrenia Bull"},{"key":"1706_CR27","unstructured":"World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology, ATC\/DDD Index 2023. 2023. https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed 23 Aug 2023."},{"key":"1706_CR28","unstructured":"Jiangsu Medical Protection Bureau Drugs and Medical Consumables Sunshine Purchasing Service Network, Volume-based drug list. http:\/\/ybj.jiangsu.gov.cn\/col\/col86465\/index.html. Assessed 31 Oct 2023."},{"issue":"20","key":"1706_CR29","doi-asserted-by":"publisher","first-page":"13319","DOI":"10.3390\/ijerph192013319","volume":"19","author":"Y Mu","year":"2022","unstructured":"Mu Y, Song K, Song Y. A cross-sectional study of price and affordability of drugs for rare diseases in Shandong Province, China. Int J Environ Res Public Health. 2022;19(20):13319.","journal-title":"Int J Environ Res Public Health"},{"key":"1706_CR30","unstructured":"Jiangsu Provincial People\u2019s Government. Jiangsu\u2019s per capita disposable income of 49,862 yuan in 2022 higher than the national average. 2023. http:\/\/www.jiangsu.gov.cn\/art\/2023\/2\/9\/art_84322_10745174.html. Assessed 13 June 2023."},{"issue":"9","key":"1706_CR31","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00535-020-01698-4","volume":"55","author":"MR Charlton","year":"2020","unstructured":"Charlton MR, Alam A, Shukla A, et al. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol. 2020;55(9):811\u201323.","journal-title":"J Gastroenterol"},{"issue":"9","key":"1706_CR32","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/apt.16611","volume":"54","author":"Z Liu","year":"2021","unstructured":"Liu Z, Jin Q, Zhang Y, et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021;54(9):1134\u201349.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9659","key":"1706_CR33","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0140-6736(08)61762-6","volume":"373","author":"A Cameron","year":"2009","unstructured":"Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis [published correction appears in Lancet. 2009 Feb 21;373(9664):632]. Lancet. 2009;373(9659):240\u20139.","journal-title":"Lancet"},{"issue":"9867","key":"1706_CR34","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S0140-6736(12)62128-X","volume":"381","author":"HV Hogerzeil","year":"2013","unstructured":"Hogerzeil HV, Liberman J, Wirtz VJ, et al. Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. Lancet. 2013;381(9867):680\u20139.","journal-title":"Lancet"},{"issue":"9","key":"1706_CR35","doi-asserted-by":"publisher","first-page":"e005519","DOI":"10.1136\/bmjgh-2021-005519","volume":"6","author":"J Yuan","year":"2021","unstructured":"Yuan J, Lu ZK, Xiong X, Jiang B. Lowering drug prices and enhancing pharmaceutical afordability: an analysis of the national volume-based procurement (NVBP) effect in China. BMJ Glob Health. 2021;6(9):e005519.","journal-title":"BMJ Glob Health"},{"issue":"5","key":"1706_CR36","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/tmi.13559","volume":"26","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Xu X, Fang W, et al. Availability, cost and affordability of selected antibiotics and antiviral medicines against infectious diseases from 2013 to 2019 in Nanjing, China. Trop Med Int Health. 2021;26(5):518\u201329. https:\/\/doi.org\/10.1111\/tmi.13559.","journal-title":"Trop Med Int Health"},{"issue":"1","key":"1706_CR37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12939-023-02006-1","volume":"22","author":"X Wang","year":"2023","unstructured":"Wang X, He X, Zhang P, et al. The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis. Int J Equity Health. 2023;22(1):200. https:\/\/doi.org\/10.1186\/s12939-023-02006-1.","journal-title":"Int J Equity Health"},{"key":"1706_CR38","unstructured":"The Latest! Summary of outpatient reimbursement policies for employees\u2019 health insurance in 13 cities in Jiangsu province out. In Jiangsu Pharmaceutical Business Association, Wechat public account. 2023. https:\/\/mp.weixin.qq.com\/s\/czl5ibPhPAgLrzzS9XzC5g. Accessed 23 Aug 2023."},{"key":"1706_CR39","unstructured":"Jiangsu Province to start the residents of medical insurance contributions: what standards, how to pay, outpatient can be reimbursed how much money? In Post-90s Coalition, Wechat public account. 2023. https:\/\/mp.weixin.qq.com\/s\/cqoZKq1Enuq0Ztuz9hwHsw. Accessed 1 Nov 2023."},{"issue":"11","key":"1706_CR40","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1046\/j.1365-3156.2001.00803.x","volume":"6","author":"P Trouiller","year":"2001","unstructured":"Trouiller P, Torreele E, Olliaro P, et al. Drugs for neglected diseases: a failure of the market and a public health failure? Trop Med Int Health. 2001;6(11):945\u201351.","journal-title":"Trop Med Int Health"},{"issue":"12","key":"1706_CR41","doi-asserted-by":"publisher","first-page":"e0241555","DOI":"10.1371\/journal.pone.0241555","volume":"15","author":"M Armstrong-Hough","year":"2020","unstructured":"Armstrong-Hough M, Sharma S, Kishore SP, et al. Variation in the availability and cost of essential medicines for non-communicable diseases in Uganda: a descriptive time series analysis. PloS One. 2020;15(12):e0241555.","journal-title":"PloS One"},{"issue":"3","key":"1706_CR42","first-page":"3371","volume":"15","author":"EK Quinn","year":"2015","unstructured":"Quinn EK, Massey PD, Speare R. Communicable diseases in rural and remote Australia: the need for improved understanding and action. Rural Remote Health. 2015;15(3):3371.","journal-title":"Rural Remote Health"},{"issue":"1","key":"1706_CR43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12939-017-0516-z","volume":"16","author":"L Si","year":"2017","unstructured":"Si L, Chen M, Palmer AJ. Has equity in government subsidy on healthcare improved in China? Evidence from the China\u2019s National Health Services Survey. Int J Equity Health. 2017;16(1):6. https:\/\/doi.org\/10.1186\/s12939-017-0516-z.","journal-title":"Int J Equity Health"},{"issue":"11","key":"1706_CR44","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.cmi.2015.07.002","volume":"21","author":"R Ozaras","year":"2015","unstructured":"Ozaras R, Corti G, Ruta S, et al. Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe. Clin Microbiol Infect. 2015;21(11):1027\u201332.","journal-title":"Clin Microbiol Infect"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01706-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-024-01706-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01706-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T18:41:58Z","timestamp":1716921718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-024-01706-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1706"],"URL":"https:\/\/doi.org\/10.1007\/s11096-024-01706-0","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"assertion":[{"value":"4 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}